Nirsevimab - Astrazeneca
Alternative Names: Anti-RSV-4-monoclonal antibody - AstraZeneca; Anti-RSV-mAb-D25; Anti-RSV-MAb-YTE; Anti-RSV-monoclonal antibody - AstraZeneca; BEYFORTUS; Beyfortus; D25; MEDI 8897; nirsevimab-alip; Respiratory-syncytial-virus-monoclonal-antibody-D25; SP 0232Latest Information Update: 22 Apr 2024
At a glance
- Originator AIMM Therapeutics
- Developer AstraZeneca; Sanofi
- Class Antivirals; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Respiratory syncytial virus infections
Most Recent Events
- 18 Apr 2024 Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends nirsevimab to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger
- 27 Mar 2024 Registered for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Japan (IM)
- 27 Mar 2024 Nirsevimab receives Priority Review Designation for Respiratory syncytial virus infections in China prior to March 2024